Pharmacokinetics, metabolism and off-target effects in the rat of 8-[(1H- benzotriazol-1-yl)amino]octanoic acid, a selective inhibitor of human cytochrome P450 4Z1: β-oxidation as a potential augmenting pathway for inhibition

References

• Al-Esawi N.S.E., et al., 2020. Expression of CYT4Z1 in breast carcinoma; Correlating with clinicopathological parameters. Biomedical and pharmacology journal, 13:1.
   Google Scholar
• Campbell, C.D., and Rees, C.W., 1969. Reactive intermediates. Part I. Synthesis and oxidation of 1- and 2-aminobenzotriazole. Journal of the chemical society, (5):742–747.
   Web of Science ®Google Scholar
• Capper, C.P., et al., 2016. The Metabolism, analysis, and targeting of steroid hormones in breast and prostate cancer. Hormones and cancer, 7:149–164.
   PubMed Web of Science ®Google Scholar
• Chovan, J.P., et al., 2007. Cytochrome P450 probe substrate metabolism kinetics in Sprague Dawley rats. Xenobiotica. 37:459–473.
   PubMed Web of Science ®Google Scholar
• Darnell, M., and Weidolf, L., 2013. Metabolism of xenobiotic carboxylic acids: focus on coenzyme A conjugation, reactivity, and interference with lipid metabolism. Chemical research in toxicology, 26:1139–1155.
   PubMed Web of Science ®Google Scholar
• Davies, B., and Morris, T., 1993. Physiological parameters in laboratory animals and humans. Pharmaceutical research, 10:1093–1095.
   PubMed Web of Science ®Google Scholar
• DeSantis, C.E., et al., 2019. Breast cancer statistics, 2019. CA: A cancer journal for clinicians, 69(6):438–451.
   PubMed Web of Science ®Google Scholar
• Faed, E.M. 1984. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug metabolism reviews, 15:1213–1249.
   PubMed Web of Science ®Google Scholar
• Guengerich, F.P., et al., 2009. Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase. Nature protocols, 4:1245–1251.
   PubMed Web of Science ®Google Scholar
• Hamilton, R.A., et al., 1981. Determination of mean valproic acid serum level by assay of a single pooled sample. Clinical pharmacology & therapeutics, 3:408–413.
   Web of Science ®Google Scholar
• He, D., et al., 2019. A novel immunodeficient rat model supports human lung cancer xenografts. The FASEB journal, 33:140–150.
   PubMed Web of Science ®Google Scholar
• Houston, J.B., 1981. Drug metabolite kinetics. Pharmacology & therapeutics, 15(3):521–552.
   PubMed Web of Science ®Google Scholar
• Iannaccone, P.M., and Jacob, H.J., 2009. Rats! Disease models & mechanisms, 2(5-6):206–210.
   PubMed Web of Science ®Google Scholar
• Kobayashi, K., et al., 2002. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochemical pharmacology, 63:889–896.
   PubMed Web of Science ®Google Scholar
• Kowalski, J.P., et al., 2020. Design and characterization of the first selective and potent mechanism-based inhibitor of cytochrome P450 4Z1. Journal of medicinal chemistry, 63(9):4824–4836.
   PubMed Web of Science ®Google Scholar
• Li, C., et al., 2006. Acyl-coenzyme a formation of simvastatin in mouse liver preparations. Drug metabolism and disposition, 34:102–110.
   PubMed Web of Science ®Google Scholar
• Li, Y., et al., 2017. Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine. Scientific reports, 7:4747.
   PubMed Web of Science ®Google Scholar
• Loi, C.M., et al., 2013. Which metabolites circulate? Drug metabolism and disposition, 41:933–951.
   PubMed Web of Science ®Google Scholar
• McDonald, M.G., et al., 2017. Expression and functional characterization of breast cancer-associated cytochrome P450 4Z1 in Saccharomyces cerevisiae. Drug metabolism and disposition, 45:1364–1371.
   PubMed Web of Science ®Google Scholar
• Mollard, S., et al., 2011. How can grafted breast cancer models be optimized? Cancer biology & therapy, 12:855–864.
   PubMed Web of Science ®Google Scholar
• Murayama, T., and Gotoh, N., 2019. Patient-derived xenograft models of breast cancer and their application. Cells, 8(6):621.
   PubMed Web of Science ®Google Scholar
• Murray, G.I., et al., 2010. Profiling the expression of cytochrome P450 in breast cancer. Histopathology, 57:202–211.
   PubMed Web of Science ®Google Scholar
• Noto, F.K., et al., 2018. Sprague dawley Rag2-null rats created from engineered spermatogonial stem cells are immunodeficient and permissive to human xenografts. Molecular cancer therapeutics, 17:2481–2489.
   PubMed Web of Science ®Google Scholar
• Obach, R.S., et al., 2007. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug metabolism and disposition, 35:246–255.
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano, P.R., 2018. 1-aminobenzotriazole: a mechanism-based cytochrome P450 inhibitor and probe of cytochrome P450 biology. Medicinal chemistry, 8(3):038.
   PubMedGoogle Scholar
• Radvanyi, L., et al., 2005. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proceedings of the national academy of sciences of the United States of America, 102:11005–11010.
   PubMed Web of Science ®Google Scholar
• Regan, S.L., et al., 2010. Acyl glucuronides: the good, the bad and the ugly. Biopharmaceutics & drug disposition . 31:367–395.
   PubMed Web of Science ®Google Scholar
• Rieger, M.A., et al., 2004. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer research, 64:2357–2364.
   PubMed Web of Science ®Google Scholar
• Rowland, M., and Tozer, T., 2011. Clinical pharmacokinetics and pharmacodynamics: Concepts and Applications. 4th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins.
   Google Scholar
• Sadeque, A.J., et al., 1992. Stereoselective sulfoxidation by human flavin-containing monooxygenase. Evidence for catalytic diversity between hepatic, renal, and fetal forms. Drug metabolism and disposition, 20:832–839.
   PubMed Web of Science ®Google Scholar
• Sarda, S., et al., 2012. Diclofenac metabolism in the mouse: novel in vivo metabolites identified by high performance liquid chromatography coupled to linear ion trap mass spectrometry. Xenobiotica. 42:179–194.
   PubMed Web of Science ®Google Scholar
• Smits, B.M., et al., 2007. Genetically engineered rat models for breast cancer. Breast disease, 28:53–61.
   PubMedGoogle Scholar
• Stanley, K.K., and Tubbs, P.K., 1975. The role of intermediates in mitochondrial fatty acid oxidation. Biochemical journal, 150:77–88.
   PubMed Web of Science ®Google Scholar
• Stewart, H. B., et al., 1973. Intermediates in fatty acid oxidation. Biochemical journal, 132:61–76.
   PubMed Web of Science ®Google Scholar
• Suga, T., 2003. Drug metabolism in peroxisomes: involvement of peroxisomal beta-oxidation system in the oxidative chain-shortening of xenobiotic acyl compounds. Drug metabolism and pharmacokinetics, 18:155–162.
   PubMedGoogle Scholar
• Vyas, K.P., et al., 1990. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse. Drug metabolism and disposition, 18:203–211.
   PubMed Web of Science ®Google Scholar
• Yang, J., et al., 2008. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Current drug metabolism, 9:384–394.
   PubMed Web of Science ®Google Scholar
• Yang, X., et al., 2017. CYP4Z1 - a human cytochrome P450 enzyme that might hold the key to curing breast cancer. Current pharmaceutical design, 23:2060–2064.
   PubMed Web of Science ®Google Scholar
• Zhang ZY and Wong YN. 2005. Enzyme kinetics for clinically relevant CYP inhibition. Current drug metabolism, 6:241–257.
   PubMed Web of Science ®Google Scholar